Spots Global Cancer Trial Database for VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Official Title: A Phase 2 Study of VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Study ID: NCT00085696
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of VELCADE when given in combination with rituximab in patients with Relapsed or Refractory Indolent B-Cell Lymphoma. This study will investigate if treatment with VELCADE and rituximab increases the time it takes your lymphoma to get worse.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA School of Medicine, Los Angeles, California, United States
Florida Cancer Specialists, Fort Myers, Florida, United States
Emory University Cancer Institute, Winship Cancer Institute, Atlanta, Georgia, United States
Georgia Cancer Specialists, Marietta, Georgia, United States
Rush University Medical Center, Chicago, Illinois, United States
Midwest Cancer Research Group, Skokie, Illinois, United States
Cancer Center of Kansas, Wichita, Kansas, United States
Oncology/Henmatology Associates of Kansas City, Kansas City, Missouri, United States
Mid Ohio Oncology/Hematology Inc., Columbus, Ohio, United States
Charleston Cancer Center, Charleston, South Carolina, United States
MD Anderson Cancer Center, Houston, Texas, United States
University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
FNVHO - US Oncology, Fairfax, Virginia, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
